Toggle navigation
Home
Search
Services
Blog
Contact
About
Transdermal. Non-Invasive Monitoring of Medication Ingestion-281033009
Sequella, Inc., Rockville, MD, United States
Search grants from Sequella, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Integrated Training in Quantitative and Experimental Cancer Systems Biology
Novel Home-Based and Low-Cost ECG Device for periodic evaluation of the presence of atrial fibrillation
Risk of Neonatal Vaccination for HIV/SIV Exposed Infants
Power and Robustness of Parametric and Nonparametric Lin
Suppressor T Cells of Mixed Leukocyte Reaction in Man
Recently added grants:
Ligand discovery for delineating cholesterol homeostasis in the brain
Mechanism of YAP/TAZ crosstalk with Wnt signaling
Effectiveness of Engaging in Advance Care Planning Talks (ENACT) Group Visits Intervention in Primary Care for Older Adults with and without Alzheimer's Dementia
Mapping & quantifying lymphatic drainage of the arms alternate pathway
Risk for Later-Life Cognitive Impairment, Neurobehavioral Dysregulation, and Dementia in Former Soccer and American Football Players: The Head Impact and Trauma Surveillance Study (HITSS)
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Small Business Innovation Research – Phase II (N44)
Project #
N44AA033009-003
Application #
6994672
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2004
Total Cost
Indirect Cost
Institution
Name
Sequella, Inc.
Department
Type
DUNS #
125129606
City
Rockville
State
MD
Country
United States
Zip Code
20850
Related projects
NIH 2004
N44 AA
Transdermal. Non-Invasive Monitoring of Medication Ingestion-281033009
/ Sequella, Inc.
NIH 2003
N44 AA
Transdermal, Non-Invasive Monitoring of Medication Ingestion-281033009
/ Sequella, Inc.
Comments
Be the first to comment on this grant